Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHRGet Rating) CEO Martine A. Rothblatt sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, January 13th. The stock was sold at an average price of $261.52, for a total transaction of $2,092,160.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $33,997.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Up 0.2 %

Shares of United Therapeutics stock opened at $260.02 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.39 and a current ratio of 9.68. United Therapeutics Co. has a 52-week low of $158.38 and a 52-week high of $283.09. The stock has a market capitalization of $11.85 billion, a price-to-earnings ratio of 17.69, a P/E/G ratio of 1.54 and a beta of 0.62. The company’s 50 day moving average price is $270.72 and its 200-day moving average price is $241.05.

United Therapeutics (NASDAQ:UTHRGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 EPS for the quarter, topping analysts’ consensus estimates of $3.57 by $1.34. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. The company had revenue of $516.00 million during the quarter, compared to analyst estimates of $492.92 million. Equities research analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research analyst reports. Morgan Stanley upped their price objective on shares of United Therapeutics from $322.00 to $330.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 6th. The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a research report on Monday, December 5th. They issued a “sell” rating and a $230.00 price objective on the stock. Argus increased their price target on shares of United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, January 11th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, November 3rd. Finally, UBS Group assumed coverage on shares of United Therapeutics in a research report on Tuesday, December 6th. They set a “buy” rating and a $320.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.64.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in United Therapeutics by 3.8% in the third quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company’s stock worth $923,703,000 after acquiring an additional 163,542 shares during the period. BlackRock Inc. lifted its position in United Therapeutics by 0.3% during the third quarter. BlackRock Inc. now owns 4,327,368 shares of the biotechnology company’s stock valued at $906,061,000 after buying an additional 13,196 shares during the period. Renaissance Technologies LLC lifted its position in United Therapeutics by 1.0% during the second quarter. Renaissance Technologies LLC now owns 2,793,591 shares of the biotechnology company’s stock valued at $658,282,000 after buying an additional 28,378 shares during the period. Wellington Management Group LLP lifted its position in United Therapeutics by 73.7% during the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after buying an additional 710,668 shares during the period. Finally, State Street Corp lifted its position in United Therapeutics by 7.2% during the first quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock valued at $291,809,000 after buying an additional 109,226 shares during the period. Hedge funds and other institutional investors own 95.63% of the company’s stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.